Standex International reports robust second-quarter results, with organic growth reaching 6.4% and record quarterly orders. The company's strategic pivot towards high-growth markets like electrical grid infrastructure and new product development is now materially boosting the top line.
The U.S. Federal Trade Commission has issued warnings to 42 prominent law firms, suggesting their diversity, equity, and inclusion hiring initiatives could violate antitrust laws by potentially restricting competition for talent.
Two financial sector giants, S&P Global and Goldman Sachs, have announced increased quarterly payouts, signaling confidence in their financial health and future prospects amid a dynamic market environment.
While the S&P 500 has climbed, Walker & Dunlop shares have tumbled over 14% in six months. We analyze the underlying weaknesses in its financials and highlight a more compelling opportunity for value-focused portfolios.
While ICF International's stock has kept pace with the broader market, analysts highlight concerns over declining backlog and slowing revenue growth, suggesting investors may find better opportunities elsewhere.
A mixed third-quarter earnings season for therapeutics stocks reveals divergent paths, with United Therapeutics missing estimates while peers like Halozyme and Biogen post strong beats. Sector-wide revenue growth and positive stock reactions suggest underlying investor confidence despite regulatory and pricing headwinds.
The United States and Argentina are in final-stage negotiations on an agreement that would see the U.S. deport migrants from third countries to the South American nation, according to a New York Times report. The potential deal aligns with the Trump administration's push to expand removal destinations and marks a sharp shift in Argentina's historically open immigration policy under President Javier Milei.
Financial services firm Lazard (LAZ) reported better-than-expected fourth-quarter results, driven by record advisory fees and robust asset growth, signaling resilience in a challenging market.
Analyst sell ratings are rare on Wall Street, making them noteworthy when they appear. We examine one such case where pessimism may have gone too far, creating a potential opportunity, alongside two stocks where the cautious outlook appears justified.
Analysts have pinned high hopes on several names, but a closer look reveals a more nuanced picture. We examine one company likely to justify the optimism and two where significant risks may be overshadowing the bullish price targets.
KeyBanc Capital Markets has upgraded LivaNova PLC (LIVN) from Sector Weight to Overweight, setting an $81 price target. The move reflects a broader positive shift in analyst sentiment towards the medical technology sector as valuation premiums ease.
Insulet Corp (PODD) has emerged as a top pick among hedge funds in the medical device sector, buoyed by overwhelmingly bullish analyst ratings and a price target suggesting significant growth potential. The company's innovative tubeless insulin pump system is seen as a key driver.
DexCom Inc. (DXCM) has released preliminary Q4 figures that exceeded expectations and provided robust long-term guidance, reinforcing its position as a favored pick among analysts and hedge funds in the medical devices sector.
Stablecoin rewards and the Clarity Act widen the divide between crypto and TradFi, according to people who spoke with the WSJ.
Allegro MicroSystems (ALGM) reported strong fourth-quarter results, with revenue surging 29% year-over-year to $229.2 million, surpassing analyst expectations. The chip designer's growth was fueled by record data center sales and robust demand in automotive, particularly for electric vehicles and ADAS.
Cavco Industries reports robust fiscal Q2 2026 earnings, with revenue up 9.7% year-over-year, driven by double-digit shipment growth in Northern U.S. markets. The company successfully managed a slowdown in the Southeast through operational adjustments and highlighted a significant turnaround in its financial services segment.
Nelnet (NNI) reaffirms its commitment to shareholders with a steady dividend, backed by strong historical revenue growth and share buybacks. Yet, a closer look reveals a complex valuation picture, with contrasting signals from its P/E ratio and discounted cash flow model, leaving analysts divided on the stock's true worth.
Navios Maritime Partners (NMM) has delivered impressive multi-year returns, leaving investors to question if its current valuation still presents an opportunity. With a diversified fleet and strong fundamentals, we examine the bull case and the risks ahead.
SLB has won significant five-year contracts from Petroleum Development Oman for the giant Block-6 field. The deals mandate local wellhead manufacturing and deploy advanced recovery technologies, anchoring SLB's long-term service role and supporting Omani job creation.
Novo Nordisk charts a bold new course, launching a pivotal oral obesity drug while restructuring its workforce and deepening its investment in next-generation cell therapies for metabolic diseases.
